{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.337","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.6"},{"groupId":"OG001","value":"60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Will be defined by the Maiolino Criteria. Will be summarized by treatment arm and compared using a chi-square test","groups":[{"description":"Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.\n\nHematopoietic Cell Transplantation: Undergo auto HSCT\n\nTbo-filgrastim: Given subcutaneously\n\nLaboratory Biomarker Analysis: Correlative Studies","id":"OG000","title":"Group I (auto HSCT tbo-filgrastim)"},{"description":"Patients undergo auto Hematopoietic Cell Transplantation (HSCT).\n\nHematopoietic Cell Transplantation: Undergo auto HSCT\n\nLaboratory Biomarker Analysis: Correlative Studies","id":"OG001","title":"Group II (auto HSCT)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 60 days","title":"Percentage of Participants With Engraftment Syndrome","type":"SECONDARY","unitOfMeasure":"percentage of participants"}